MX9304503A - Compuestos antiinflamatorios. - Google Patents

Compuestos antiinflamatorios.

Info

Publication number
MX9304503A
MX9304503A MX9304503A MX9304503A MX9304503A MX 9304503 A MX9304503 A MX 9304503A MX 9304503 A MX9304503 A MX 9304503A MX 9304503 A MX9304503 A MX 9304503A MX 9304503 A MX9304503 A MX 9304503A
Authority
MX
Mexico
Prior art keywords
present
relates
inflammatory compounds
lipoxygenase
cyclooxygenase
Prior art date
Application number
MX9304503A
Other languages
English (en)
Spanish (es)
Inventor
Simon Teanby Hodgson
David Evan Davies
Steven Smith
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of MX9304503A publication Critical patent/MX9304503A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/64Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX9304503A 1992-07-27 1993-07-26 Compuestos antiinflamatorios. MX9304503A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929215921A GB9215921D0 (en) 1992-07-27 1992-07-27 Anti-inflammatory compounds

Publications (1)

Publication Number Publication Date
MX9304503A true MX9304503A (es) 1994-04-29

Family

ID=10719360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304503A MX9304503A (es) 1992-07-27 1993-07-26 Compuestos antiinflamatorios.

Country Status (10)

Country Link
EP (1) EP0652864A1 (cg-RX-API-DMAC10.html)
JP (1) JPH07509462A (cg-RX-API-DMAC10.html)
AU (1) AU672810B2 (cg-RX-API-DMAC10.html)
CA (1) CA2141214A1 (cg-RX-API-DMAC10.html)
GB (1) GB9215921D0 (cg-RX-API-DMAC10.html)
IL (1) IL106472A0 (cg-RX-API-DMAC10.html)
MX (1) MX9304503A (cg-RX-API-DMAC10.html)
TW (1) TW246670B (cg-RX-API-DMAC10.html)
WO (1) WO1994002448A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA935378B (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL314605A1 (en) * 1993-11-26 1996-09-16 Pfizer Isoxazolin compounds as anti-inflammatory agents
WO1995024192A1 (en) * 1994-03-09 1995-09-14 Pfizer Inc. Isoxazoline compounds as 5-lipoxygenase inhibitors
EP0807626A4 (en) * 1995-02-02 1998-05-06 Nikken Chemicals Co Ltd N-HYDROXYUREA DERIVATIVES
WO1997029775A1 (en) 1996-02-13 1997-08-21 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist
WO1997029774A1 (en) 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
ATE210461T1 (de) 1996-02-13 2001-12-15 Searle & Co Zusammensetzungen mit immunosuppressiven wirkungen, welche 5-lipoxygenase-inhibitoren und cyclooxygenase-2-inhibitoren enthalten
ATE224718T1 (de) * 1996-06-25 2002-10-15 Cephalon Inc Verwendung eines k-252a derivats zur behandlung von periphärer oder zentraler nervenerkrankungen und übermässiger cytokinbildung
ES2189207T3 (es) * 1997-07-31 2003-07-01 Abbott Lab Inhibidores de hidroxamatos inversos de metaloproteinasas matriciales.
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
WO2000044712A1 (en) * 1999-01-27 2000-08-03 Abbott Laboratories N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
SE0103325D0 (sv) 2001-10-04 2001-10-04 Astrazeneca Ab Novel compounds
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602485B2 (en) * 1985-03-16 1990-10-18 Wellcome Foundation Limited, The Lipoxygenase and/or cyclooxygenase inhibitory compounds
PL154186B1 (en) * 1987-07-15 1991-07-31 Wellcome Found Method for manufacturing arylic derivatives of the hydroxamic acid
DE69122759T2 (de) * 1990-07-25 1997-05-15 Abbott Lab Acetylenderivate mit lipoxygenase inhibitorischer wirkung
JPH06256285A (ja) * 1990-12-11 1994-09-13 Pfizer Pharmaceut Co Ltd ヒドロキサム酸誘導体およびその用途

Also Published As

Publication number Publication date
JPH07509462A (ja) 1995-10-19
WO1994002448A1 (en) 1994-02-03
AU4717093A (en) 1994-02-14
TW246670B (cg-RX-API-DMAC10.html) 1995-05-01
CA2141214A1 (en) 1994-02-03
IL106472A0 (en) 1993-11-15
AU672810B2 (en) 1996-10-17
ZA935378B (en) 1995-01-26
EP0652864A1 (en) 1995-05-17
GB9215921D0 (en) 1992-09-09

Similar Documents

Publication Publication Date Title
MX9304503A (es) Compuestos antiinflamatorios.
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
ES2233931T3 (es) Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos.
DE69912606D1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivate
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
ES2159382T3 (es) Compuestos estilbenicos con grupo adamantilo, composiciones que los contienen y utilizaciones.
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
EA199700380A1 (ru) Бициклические ароматические соединения, фармацевтическая и косметическая композиции на их основе и применение косметической композиции
ES2130152T3 (es) Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
AR005860A1 (es) Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen, y su utilización.
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
BR0111678A (pt) Composições medicinais contendo derivados de propenona
AR035889A1 (es) Citrato de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9- pentaeno y composiciones farmaceuticas que la contienen y su uso para la elaboracion de medicamentos
BR0014895A (pt) Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
ES2129112T3 (es) Compuestos aromaticos policiclicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2087623T3 (es) Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon.
UY28943A1 (es) Nucleósidos de 3-b (beta)-d-ribofuranosiltiazolo(4,5-d) pirimidina y sus usos
AR026257A1 (es) N-guanidinoalquilamidas, su preparacion, su uso y composiciones farmaceuticas que las contienen
ES2163805T3 (es) Derivados de acidos benzofurano-acrilicos y su utilizacion como moduladores de los receptores rxrs o rars.
AR032553A1 (es) Derivados de alfa-amino-n-hidroxi-acetamida.